Article Text
Abstract
Background: The CpG island methylator phenotype (CIMP or CIMP-high) with widespread promoter methylation is a distinct epigenetic phenotype in colorectal cancer. In contrast, a phenotype with less widespread promoter methylation (CIMP-low) has not been well characterised. O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and silencing have been associated with G>A mutations and microsatellite instability-low (MSI-low).
Aim: To examine molecular correlates with MGMT methylation/silencing in colorectal cancer.
Methods: Utilising MethyLight technology, we quantified DNA methylation in MGMT and eight other markers (a CIMP-diagnostic panel; CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) in 920 population-based colorectal cancers.
Results: Tumours with both MGMT methylation and loss were correlated positively with MSI-low (p = 0.02), CIMP-high (⩾6/8 methylated CIMP markers, p = 0.005), CIMP-low (1/8–5/8 methylated CIMP markers, p = 0.002, compared to CIMP-0 with 0/8 methylated markers), KRAS G>A mutation (p = 0.02), and inversely with 18q loss of heterozygosity (p = 0.0002). Tumours were classified into nine MSI/CIMP subtypes. Among the CIMP-low group, tumours with both MGMT methylation and loss were far more frequent in MSI-low tumours (67%, 12/18) than MSI-high tumours (5.6%, 1/18; p = 0.0003) and microsatellite stable (MSS) tumours (33%, 52/160; p = 0.008). However, no such relationship was observed among the CIMP-high or CIMP-0 groups.
Conclusion: The relationship between MGMT methylation/silencing and MSI-low is limited to only CIMP-low tumours, supporting the suggestion that CIMP-low in colorectal cancer may be a different molecular phenotype from CIMP-high and CIMP-0. Our data support a molecular difference between MSI-low and MSS in colorectal cancer, and a possible link between CIMP-low, MSI-low, MGMT methylation/loss and KRAS mutation.
- colon cancer
- MGMT
- CpG island methylator phenotype
- CIMP
- microsatellite instability
Statistics from Altmetric.com
Footnotes
Funding: This work was supported by the US National Institute of Health (NIH) grants P01 CA87969 and P01 CA55075.
Competing interests: None.
- Abbreviations:
- CACNA1G
- calcium channel, voltage-dependent, T type alpha-1G subunit
- CDKN2A
- cyclin-dependent kinase inhibitor 2A (p16/INK4A)
- CIMP
- CpG island methylator phenotype
- CRABP1
- cellular retinoic acid binding protein 1
- DAB
- diaminobenzidine
- HNPCC
- hereditary non-polyposis colorectal cancer
- IGF2
- insulin-like growth factor 2
- LOH
- loss of heterozygosity
- MGMT
- O-6-methylguanine-DNA methyltransferase
- MSI
- microsatellite instability
- MSI-H
- microsatellite instability-high
- MSI-L
- microsatellite instability-low
- MSS
- microsatellite stable
- NCI
- National Cancer Institute
- NEUROG1
- neurogenin 1
- PMR
- percentage of methylated reference (degree of methylation)
- RUNX3
- runt-related transcription factor 3
- SOCS1
- suppressor of cytokine signaling 1
- TGFBR2
- transforming growth factor-beta receptor type 2
- WGA
- whole genome amplification
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.